Yeramian Patrick D

SEC source: 0000950170-24-003974 · ownership.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,605

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-23-022775 · ownership.xml · derivative · entry 5

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,770

Underlying: Common Stock · 9,764 shares

Expires 2031-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F4 · derivative.exercise_date: As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.

SEC source: 0000950170-23-022775 · ownership.xml · derivative · entry 4

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,404

Underlying: Common Stock · 2,201 shares

Expires 2029-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F3 · derivative.exercise_date: As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.

SEC source: 0000950170-23-022775 · ownership.xml · nonDerivative · entry 3

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,417

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-23-022775 · ownership.xml · nonDerivative · entry 2

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,382

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

SEC source: 0000950170-23-022775 · ownership.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,618

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

SEC source: 0000899243-23-011461 · doc4.xml · derivative · entry 6

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,534

Underlying: Common Stock · 4,718 shares

Expires 2031-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F4 · derivative.exercise_date: As of the date of this filing, 18,464 shares subject to the option are vested and exercisable. 29,788 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.

SEC source: 0000899243-23-011461 · doc4.xml · derivative · entry 5

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,605

Underlying: Common Stock · 44,861 shares

Expires 2029-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F3 · derivative.exercise_date: As of the date of this filing, 44,861 shares subject to the option are vested and exercisable. 17,605 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.

SEC source: 0000899243-23-011461 · doc4.xml · nonDerivative · entry 4

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,417

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

SEC source: 0000899243-23-011461 · doc4.xml · nonDerivative · entry 3

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,717

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-23-011461 · doc4.xml · nonDerivative · entry 2

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

SEC source: 0000899243-23-011461 · doc4.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 253,278

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

SEC source: 0000899243-23-009178 · doc4.xml · derivative · entry 4

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 41,250 shares

Expires 2033-03-16

F5 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0000899243-23-009178 · doc4.xml · nonDerivative · entry 3

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,839

F4 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0000899243-23-009178 · doc4.xml · nonDerivative · entry 2

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,672

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-23-009178 · doc4.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,088

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 10

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,252

Underlying: Common Stock · 16,748 shares

Expires 2031-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F9 · derivative.exercise_date: 16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter.

SEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 9

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,466

Underlying: Common Stock · 30,041 shares

Expires 2029-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F8 · derivative.exercise_date: As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.

SEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 8

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,789 shares

Expires 2028-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F7 · derivative.exercise_date: The shares subject to such option are vested and currently exercisable.

SEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 7

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 41,250 shares

Expires 2033-03-16

F6 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 6

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,417

F5 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

SEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 5

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,250

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

SEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 4

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,666

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

SEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 3

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,877

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

SEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 2

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,129

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

SEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,088

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.

F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.

SEC source: 0000899243-23-001526 · doc4.xml · nonDerivative · entry 2

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,299

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-23-001526 · doc4.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,928

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-22-001522 · doc4.xml · derivative · entry 2

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,500

Underlying: Common Stock · 127,500 shares

Expires 2032-01-06

F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

SEC source: 0000899243-22-001522 · doc4.xml · nonDerivative · entry 1

Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,333

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.